In conclusion, integrative mutational and clinical analyses reveal that considering JAK2, RUNX1 mutation status and BM blast percentage (> 1.5%) can further improve risk stratification of disease progression and over survival among the patients with LR-MDS in the context of IPSS-R. The gene discussed is JAK2; the disease is myelodysplastic syndrome.